PKPD illustration

Pharmacokinetics & Pharmacodynamics

Explore BRAFTOVI® + MEKTOVI® PK-PD properties

MAP pathway

BRAFTOVI® (encorafenib) is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor. MEKTOVI® (binimetinib) is an ATP-uncompetitive, reversible inhibitor of the kinase activity of the MEK kinase 1 & 2.1,2

When BRAFTOVI® is used in combination with MEKTOVI® it shows a greater antiproliferative activity compared with monotherapy9.


Watch the video to learn more on the combination PK-PD profile

Allow powerful and sustained target suppression9,10

PKPD characteristics

Note: No direct link between pharmacological properties of molecules and their clinical efficacy can be established.

PD, pharmacodynamic; PK, pharmacokinetic; MEK, Mitogen-activated Extracellular signal regulated kinase; RAF, Rapidly Accelerated Fibrosarcoma. 
aAllows a prolonged inhibition of pERK due to its long dissociation half-life.9 bAllows for increased doses of BRAFTOVI due to its ameliorative effect on toxicity.11

HealthCare Professionals​

This is an international website for BRAFTOVI® + MEKTOVI® dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am Healthcare Professional outside the US and I have read the information above​.


This is an international website for BRAFTOVI® + MEKTOVI® dedicated to Healthcare Professionals.

I am a patient outside the US​.